(Q47281516)

13 January 2018

review article

1 reference

title

Low-molecular-weight heparins: pharmacologic profile and product differentiation (English)

1 reference

13 January 2018

1 reference

J Fareed

1

1 reference

13 January 2018

W Jeske

2

1 reference

13 January 2018

D Hoppensteadt

3

1 reference

13 January 2018

R Clarizio

4

1 reference

13 January 2018

J M Walenga

5

1 reference

13 January 2018

language of work or name

English

0 references

publication date

1 September 1998

1 reference

13 January 2018

American Journal of Cardiology

published in

1 reference

13 January 2018

volume

82

1 reference

13 January 2018

issue

5B

1 reference

13 January 2018

page(s)

3L-10L

1 reference

13 January 2018

A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900105-2

Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900105-2

Rat jugular vein hemostasis--a new model for testing antithrombotic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900105-2

A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900105-2

A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900105-2

Monitoring of low-molecular-weight heparins in cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900105-2

Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular-weight heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900105-2

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900105-2

Low-molecular-weight heparin in the treatment of patients with venous thromboembolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900105-2

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900105-2

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900105-2

Heparin in Acute Coronary Disease — Requiem for a Heavyweight?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900105-2

10.1016/S0002-9149(98)00105-2

7 January 2021

Identifiers

DOI

1 reference

13 January 2018

PubMed ID

9737473

1 reference

13 January 2018